Using the Global Health Sector Strategy and its 2025 targets to drive change 

World Health Organization’s (WHO) new Global Health Sector Strategy (GHSS) on HIV, viral hepatitis and sexually transmitted infections (STIs) promotes the disease specific goals to end AIDS and the epidemics of viral hepatitis and STIs by 2030. The new strategies propose a common vision to end epidemics and advance universal health coverage, primary health care and health security in a world where all people have access to high-quality, evidence-based and people-centered health services.  

The new GHSS sets out interim 2025 targets that countries will need to work towards. With less than three years till these interim targets and eight years until the 2030 targets, most countries must accelerate their efforts to achieve them.  

Resource toolkit for community organisations

We have developed a brief toolkit to summarise what the GHSS means for civil society and community organisations and equip them to use the GHSS as a tool to support advocacy efforts and drive hepatitis-related policies.  

As part of this, we have provided a template letter, co-signed by WHA, for civil society and community organisations to adapt and use to engage their health ministers and governments. 

Webinar

Watch our webinar: Hepatitis Can’t Wait: Using the Global Health Sector Strategy and its 2025 targets to drive change. 

We were joined by expert speakers who discussed: 

  • An overview of the new GHSS, the five strategic directions, and the 2025 and 2030 targets.  
  • The progress countries have made to these goals and what needs to be done to achieve them.   
  • How community-based organisations and activists can use the GHSS and its targets for advocacy and to hold countries and health systems accountable to their commitments.  
  • Good practice examples of using the previous GHSS for advocacy and how countries have used GHSS in the planning and implementation of their national programmes.   

Watch it here ➡️

Speakers:

Chair: Danjuma Adda, President, World Hepatitis Alliance (WHA); and Executive Director, Center for Initiative and Development (CFID) and Chagro-Care Trust (CCT) 

Dr Olufunmilayo Lesi, Global HIV, Hepatitis and STIs Programmes Lead, World Health Organization (WHO) 

Devin Razavi-Shearer, Associate Director of hepatitis B, Center for Disease Analysis Foundation (CDAF) 

Honourable Éctor Jaime Ramírez Barba, MD and Member of Parliament, Mexico 

This webinar is supported by AbbVie.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close